Phase 4Status unknown
Efficacy and Safety of Efsubaglutide Alfa in Patients with Prediabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Sponsor
- Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
- Enrollment
- 130 planned
- Conditions
- Prediabetes
- Interventions
- All participants will receive unified lifestyle intervention guidance and be treated with efsubaglutide alfa injection; All participants will receive unified lifestyle intervention guidance and be treated with matching placebo injection
- Ages
- adults, older adults
- Registry
- ChiCTR2600130237
Full record on the Chinese Clinical Trial RegistrySource: WHO ICTRP, processed August 24, 2026
Primary outcomes
- Remission rate of prediabetes after 24 weeks of treatment;
History
Last registry update
Registered
Started